Streetbeat News

Regulatory

HTOO

Fusion Fuel Green PLC (NASDAQ:HTOO) shares surged in premarket trading after the company announced its HEVO-Portugal project was selected for approval under the European Commission's IPCEI Hy2Infra program. The project, valued at €650 million, aims to produce 62,000 tonnes of green hydrogen annually in Sines, Portugal. This approval allows Fusion Fuel to begin funding discussions with government entities and the European Investment Bank.

Portfolio Pulse from Nabaparna Bhattacharya

February 16, 2024 | 1:32 pm

SPY

USA Building Permits for January decreased by 1.5%, missing the estimated 1.3% increase and showing a decline from the previous 1.8% growth.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 1:32 pm

SPY

USA Building Permits for January were reported at 1.470M, falling short of the estimated 1.509M and the previous month's 1.493M.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 1:31 pm

SRPT

Sarepta Therapeutics' stock is trading higher following the FDA's acceptance and filing of the company's efficacy supplement for ELEVIDYS to the Biologics License Application.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 1:23 pm

IXHL

Incannex has completed a successful Pre-IND meeting with the FDA for CannQuit-N, a novel solution aimed at tobacco smoking cessation. This marks a significant step forward in the development and potential approval process of CannQuit-N.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 12:39 pm

CASI

CASI Pharmaceuticals announced the first dosing of Folotyn in China, marking a significant milestone for the company's expansion in the Chinese market.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 12:13 pm

TELL

Tellurian Inc. has received an extension from the U.S. Federal Energy Regulatory Commission for its Driftwood LNG project. This extension is a significant regulatory milestone for Tellurian, potentially impacting the project's timeline and financial outlook.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 12:10 pm

SRPT

Sarepta Therapeutics has announced that the FDA has accepted an efficacy supplement for ELEVIDYS, aimed at expanding its indication for Duchenne muscular dystrophy (DMD) treatment and converting its accelerated approval to traditional approval. The FDA has granted priority review with a goal date of June 21, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 12:02 pm

GLPG

Galapagos is set to present new and previously disclosed data from its EUPLAGIA-1 Phase 1/2 study at the European Society for Blood and Marrow Transplantation. The new data highlights the potential of Galapagos' CAR-T manufacturing platform in treating patients with severe hematologic cancers, including chronic lymphocytic leukemia and Richter transformation. The platform's ability to produce robust expansion and persistence of CAR-T cells from a single infusion is emphasized, alongside supporting safety, efficacy, and feasibility data.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:10 am

XOM

The New York State Common Retirement Fund is restricting investments in eight oil and gas companies, including Exxon Mobil Corp (NYSE:XOM), due to climate change concerns. The fund plans to divest its corporate bonds and actively manage public equity holdings in these companies, deemed not transition-ready for a sustainable future. The total value of these holdings is approximately $26.8 million, with around $25 million in Exxon shares to be divested, while maintaining about $500 million in other Exxon holdings in passive index funds.

Portfolio Pulse from Lekha Gupta

February 16, 2024 | 10:54 am